5 Key Things You Should Watch With Jazz Pharmaceuticals
It's been a great year for Jazz Pharmaceuticals (NASDAQ: JAZZ) shareholders so far. The biotech stock is up more than 35% year to date. However, most of those gains were made in the first quarter, thanks to positive clinical results. Over the last five months, Jazz stock has retreated every time it seems to pick up momentum.
Jazz Pharmaceuticals CEO Bruce Cozzad sat down at the Wells Fargo Healthcare Conference on Wednesday to field questions. Perhaps the most important question posed to Cozzad related to what investors should watch for in the rest of 2017 and into 2018. Here are the five key things Jazz's CEO listed in his response.
Image source: Getty Images.
Source: Fool.com